國家衛生研究院 NHRI:Item 3990099045/15514
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 911743      線上人數 : 953
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/15514


    題名: Risk of type 2 diabetes mellitus and hyperlipidemia in patients with chronic myeloid leukemia initiating tyrosine kinase inhibitors: A nationwide cohort study
    作者: Huang, RY;Tsai, HJ;Hsieh, KP;Chen, LT;Yang, YH
    貢獻者: National Institute of Cancer Research
    摘要: Background: The development of tyrosine kinase inhibitor (TKI) improves the survival of chronic myeloid leukemia (CML). Adverse effects following long-term treatment are of concern. Current results regarding metabolic effects of TKI are limited. Objectives: To investigate the risk of type 2 diabetes mellitus (T2DM) and hyperlipidemia (HLD) in CML patients with TKI therapy using real-world data setting. Methods: This retrospective cohort study identified CML patients with aged 20 years old or older from Taiwan Cancer Registry (2010–2018) and extracted their corresponding TKI therapy information from nationwide claim database (2010–2020). Patients with other cancers and with DM or HLD history before TKI therapy were excluded. The DM and HLD cohorts were generated separately. Patients were grouped by their first-line TKI therapy including imatinib, dasatinib and nilotinib. They were followed from TKI initiation to new-onset T2DM or HLD, death, or up to 90 days after treatment discontinuation or switched to another TKI, or the end of database (2020 DEC 31). Multivariable Cox regression was performed to estimate the risks of T2DM or HLD. Results: There were 1359 and 1307 patients in T2DM (41.4% imatinib, 28.7% dasatinib, 29.9% nilotinib) and HLD (41.5% imatinib, 28.7% dasatinib, 29.8% nilotinib) cohorts, respectively. For the risk of T2DM, the comparison among the first-line dasatinib, imatinib and nilotinib users showed no significant difference. The risk of HLD was occurred in nilotinib users, which was 2.83 (HR, 95%CI = 1.96–4.09, p< 0.001) times that of imatinib users and 1.69 (95%CI = 1.10–2.60, p = 0.017) times that of dasatinib users. There was no significant difference for HLD occurrence among the 3 drugs when patients with history of hypertension, diabetes, higher comorbidity scores (2 or more), or older age. In patients without history of hypertension (nilotinib vs imatinib, HR = 3.74, 95%CI = 2.38–5.87, p< 0.001; nilotinib vs dasatinib, HR = 1.87, 95%CI = 1.24–2.82, p = 0.003), without history of coronary artery disease/ischemic heart disease (nilotinib vs imatinib, HR = 3.0; 95%CI = 2.05–4.41, p< 0.001; nilotinib vs dasatinib, HR = 1.67; 95%CI = 1.15–2.43, p-value = 0.008) or without diabetes (nilotinib vs imatinib, HR = 2.96, 95% CI = 2.00–4.37, p< 0.001; nilotinib vs dasatinib, HR = 1.80, 95%CI = 1.21–2.68, p = 0.004), significantly higher risks of HLD were found in the nilotinib group. Conclusions: The first-line nilotinib users had significantly higher risk of HLD, followed by dasatinib as compared to imatinib users. There was no significantly difference in the risk of T2DM among three TKI users. Our results suggest that a routine monitoring of lipid profile might be necessary for CML patients with nilotinib or dasatinib.
    日期: 2023-10
    關聯: Pharmacoepidemiology and Drug Safety. 2023 Oct;32(Suppl. S1):575.
    Link to: https://doi.org/10.1002/pds.5687
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1053-8569&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001091511702371
    顯示於類別:[蔡慧珍] 會議論文/會議摘要
    [陳立宗] 會議論文/會議摘要
    [楊奕馨] 會議論文/會議摘要

    文件中的檔案:

    檔案 大小格式瀏覽次數
    ISI001091511702371.pdf1215KbAdobe PDF595檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋